Fate Therapeutics (FATE) Stock Price
Fate Therapeutics Price
Revenue has compounded at 13.2% per year over the past 14 years to 6.65 M USD. Fate Therapeutics's net margin stands at -2,051.1%, down from -379.9% several years earlier. Analysts set a median price target of 5.50 USD, implying 166.3% above the current price. Of 18 analysts, 11 rate the stock a buy — an overall Buy consensus.
Fate Therapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Fate Therapeutics business model & stock analysis
Frequently asked questions about Fate Therapeutics
The business model of Fate Therapeutics Inc revolves around the development and commercialization of cellular immunotherapies for the treatment of various diseases. The company focuses on utilizing advanced techniques to enhance the therapeutic potential of immune cells, including natural killer (NK) cells and T-cells. By engineering these cells with proprietary techniques, Fate Therapeutics aims to create more effective and targeted treatments for patients. With a strong emphasis on innovation and clinical development, Fate Therapeutics strives to bring transformative therapies to market, addressing unmet medical needs. Hamilton: Your Personal Stock Assistant
Fate Therapeutics Inc primarily operates in the biotechnology and pharmaceutical industries. The company focuses on the development and commercialization of cellular immunotherapies for the treatment of cancer and other immune disorders. Fate Therapeutics utilizes its proprietary induced pluripotent stem cell (iPSC) product platform to optimize the therapeutic potential of immune cells. By harnessing the power of cellular reprogramming, Fate Therapeutics aims to revolutionize the field of medicine and improve patient outcomes. With a relentless commitment to innovation, Fate Therapeutics strives to address unmet medical needs and make a lasting impact in the healthcare industry.
The main competitors of Fate Therapeutics Inc in the market include companies such as bluebird bio Inc, CRISPR Therapeutics AG, Sangamo Therapeutics Inc, and Editas Medicine Inc.
Fate Therapeutics Inc is a biopharmaceutical company specializing in the development of off-the-shelf cellular immunotherapies for patients with cancer and immune disorders. It was founded in 2007 by world-renowned stem cell experts: Dr. Rudolf Jaenisch, Dr. Sheng Ding, Dr. Leonard Zon, and Dr. Michael Clarke. The company's goal is to harness the power of stem cells and advance breakthrough therapies using induced pluripotent stem cell (iPSC) technology. Fate Therapeutics has since grown into a leading player in the field, with a diverse pipeline of innovative therapies and strategic partnerships. With its strong scientific foundation and commitment to improving patient outcomes, Fate Therapeutics continues to drive advancements in the field of cellular immunotherapies.
Fate Therapeutics Inc has achieved several significant milestones. The company received the U.S. Food and Drug Administration (FDA) clearance for its investigational new drug (IND) application for FT516, an off-the-shelf natural killer (NK) cell cancer immunotherapy. This milestone allows the company to initiate clinical trials and assess the safety and efficacy of FT516 in treating certain types of cancer. Additionally, Fate Therapeutics Inc has received the FDA Fast Track designation for FT516 in combination with monoclonal antibody therapy. These milestones highlight the company's commitment to advancing innovative cell therapies and its potential to revolutionize cancer treatment.
Fate Therapeutics Inc is primarily present in the United States.
Fate Therapeutics Inc represents a strong commitment to advancing the field of cellular immunotherapy. With a focus on harnessing the power of cells to develop innovative cancer treatments, Fate Therapeutics prioritizes developing transformative therapies that address unmet medical needs. The company embraces a corporate philosophy of scientific rigor, innovation, and collaboration to deliver cutting-edge therapies to patients who need them. By leveraging their proprietary cell programming platform, Fate Therapeutics aims to revolutionize the way cancer and other diseases are treated.
Analysts currently set an average price target of 5.63 USD for the Fate Therapeutics stock (median: 5.50 USD), implying +172.6 % versus the latest price. The consensus is based on 18 analyst ratings.
18 analysts currently rate the Fate Therapeutics stock: 11 recommend buying, 7 holding and 0 selling. For 2026, analysts expect Fate Therapeutics to generate revenue of 5.61 M USD and earnings per share of -1.07 USD.
Converted at the current exchange rate, the Fate Therapeutics share trades at 1.84 EUR (2.07 USD).
The Fate Therapeutics share (FATE) is listed on 4 stock exchanges, including: NASDAQ (FATE), Frankfurt (F6T.F), München (F6T.MU), Düsseldorf (F6T.DU).
Fate Therapeutics Inc. is an American biotechnology company specializing in the development of therapeutic products for serious diseases. It was founded in 2007 and is headquartered in San Diego, California. The company focuses on the development of stem cell therapy and immunotherapy products based on the use of induced pluripotent stem cells (iPS cells) and natural killer cells (NK cells). These products are used in regenerative medicine for the treatment of serious diseases, especially cancer and genetic disorders. Fate Therapeutics operates in three main areas: iPS cell production, NK cell research, and immuno-toxicity. The company offers pluripotent cell lines (PiSCLs) that allow researchers to access its technology for cell reprogramming and iPS cell production. In the NK cell research field, the company is developing potent NK cell products for fighting tumor cells and treating infections and other serious diseases. Fate Therapeutics also offers immune-toxicity products to minimize toxic risks in the development of new drugs. The company is focused on research and development and has partnerships with other biotechnology companies such as Celgene to further its therapeutic product development. Its business model is based on developing and commercializing new cellular therapy products for the treatment of serious diseases. Fate Therapeutics is a leading provider in stem cell therapy and immunotherapy products, and with its innovative products and advanced technologies, it is well positioned to make further scientific advancements in the future and revolutionize the healthcare industry.
The expected revenue of Fate Therapeutics is 5.61 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Fate Therapeutics is -126.87 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Fate Therapeutics is currently -1.93. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fate Therapeutics stock.
The price-to-sales ratio (P/S) of Fate Therapeutics is currently 43.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fate Therapeutics stock.
The Eulerpool Quality Score for Fate Therapeutics is 3/10.
The ISIN of Fate Therapeutics is US31189P1021. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Fate Therapeutics is A1W50M. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Fate Therapeutics is FATE. The ticker symbol is used to trade Fate Therapeutics shares on the stock exchange.
Fate Therapeutics stock
Fate Therapeutics Peer Group
Fate Therapeutics Ticker
Fate Therapeutics FIGI
All fundamentals and in-depth analysis of Fate Therapeutics
Our stock analysis for Fate Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fate Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.